TVM Life Science Management

Other

TVM Life Science Management

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem. Sign in

TVM Life Science Management

Address

Ottostraße 4
80333 Munich, Germany

Contact

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem.

Matchmaking

Connect with TVM Life Science Management

Position on the value chain

With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

TVM Life Science Management last news

20/07/2023

Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis

Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis Novel antibody specifically designed for oral administration utilizes Tillotts Pharma's sustained release approach to ensure optimal and local treatment Mage Biologics is the 10th early-stage or project focused company (PFC) investment for TVM Life Science Innovation II Fund Montreal, Canada / Munich, Germany / Rheinfelden, […] The post Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis appeared first on TVM Capital Life Science Venture Capital .

17/03/2023

TVM Capital Life Science to participate in LSI USA '23 Emerging Medtech Summit 2023

Company highlights key investments from its commercial-stage medtech portfolio Montreal, Canada / Munich, Germany – 17 March 2023 – TVM Capital Life Science ("TVM"), a leading international venture capital firm focused on investments in life sciences innovation, today announced that Dr. Luc Marengère, Managing Partner, and Dr. Sascha Berger, General Partner of TVM, will participate […] The post TVM Capital Life Science to participate in LSI USA '23 Emerging Medtech Summit 2023 appeared first on TVM Capital Life Science Venture Capital .

23/02/2023

TVM Capital Life Science Announces Promotions to Recognize Significant Contributions of Up-and-Coming Leaders

Montreal, Canada / Munich, Germany – 23 February 2023 – TVM Capital Life Science ("TVM"), a leading international venture capital firm focused on investments in life sciences innovation, today announced the promotion of Dr. Valentina Agostoni and Catello Somma to Senior Associate and Philipp Lechner to Senior Associate Corporate Finance. "I congratulate our three talented […] The post TVM Capital Life Science Announces Promotions to Recognize Significant Contributions of Up-and-Coming Leaders appeared first on TVM Capital Life Science Venture Capital .